LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Home・Aktien・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

Max

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	-0.05% downside

Mirati Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Nov. 2025, 17:45 UTC

Ergebnisse

Wichtige Markttreiber

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14. Nov. 2025, 17:31 UTC

Ergebnisse

Wichtige Markttreiber

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

14. Nov. 2025, 16:15 UTC

Wichtige Markttreiber

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

14. Nov. 2025, 23:56 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14. Nov. 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14. Nov. 2025, 22:35 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14. Nov. 2025, 22:32 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14. Nov. 2025, 22:29 UTC

Ergebnisse

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14. Nov. 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14. Nov. 2025, 21:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

14. Nov. 2025, 21:18 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14. Nov. 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14. Nov. 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14. Nov. 2025, 20:17 UTC

Akquisitionen, Fusionen, Übernahmen

Several State Attorneys General Oppose Railroad Merger -- WSJ

14. Nov. 2025, 19:29 UTC

Market Talk

Ergebnisse

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14. Nov. 2025, 18:44 UTC

Market Talk

Ergebnisse

Disney's Growth Now Hinges More on ESPN -- Market Talk

14. Nov. 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14. Nov. 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14. Nov. 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14. Nov. 2025, 17:20 UTC

Market Talk

Ergebnisse

Auto & Transport Roundup: Market Talk

14. Nov. 2025, 17:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

14. Nov. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14. Nov. 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14. Nov. 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14. Nov. 2025, 16:38 UTC

Market Talk

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

14. Nov. 2025, 16:30 UTC

Akquisitionen, Fusionen, Übernahmen

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14. Nov. 2025, 16:28 UTC

Market Talk

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

14. Nov. 2025, 15:59 UTC

Market Talk

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

14. Nov. 2025, 15:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. Nov. 2025, 15:06 UTC

Market Talk

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

Peer-Vergleich

Kursveränderung

Mirati Therapeutics Inc Prognose

Kursziel

By TipRanks

-0.05% Nachteil

12-Monats-Prognose

Durchschnitt 58.67 USD -0.05%

Hoch 59 USD

Tief 58 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Mirati Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Mirati Therapeutics Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

EBITDA

Betriebsergebnis

Über Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.